A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma
Latest Information Update: 29 Apr 2024
At a glance
- Drugs Daratumumab/hyaluronidase (Primary)
- Indications Smoldering multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms AQUILA
- Sponsors Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
- 30 Jan 2024 Planned End Date changed from 10 Dec 2025 to 11 Jul 2025.
- 05 Dec 2023 Planned primary completion date changed from 30 Sep 2024 to 1 May 2024.
- 03 May 2023 Planned End Date changed from 22 Dec 2025 to 10 Dec 2025.